These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 37433816)

  • 21. Current state of Ebola virus vaccines: A snapshot.
    Woolsey C; Geisbert TW
    PLoS Pathog; 2021 Dec; 17(12):e1010078. PubMed ID: 34882741
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice.
    Ma J; Boudewijns R; Sanchez-Felipe L; Mishra N; Vercruysse T; Buh Kum D; Thibaut HJ; Neyts J; Dallmeier K
    Emerg Microbes Infect; 2021 Dec; 10(1):2279-2290. PubMed ID: 34792431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Present and Future of Yellow Fever Vaccines.
    Hansen CA; Barrett ADT
    Pharmaceuticals (Basel); 2021 Sep; 14(9):. PubMed ID: 34577591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ebola vaccines for mass immunisation in affected regions.
    Agnandji ST; Loembe MM
    Lancet Infect Dis; 2022 Jan; 22(1):8-10. PubMed ID: 34529960
    [No Abstract]   [Full Text] [Related]  

  • 25. Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks.
    Keita AK; Koundouno FR; Faye M; Düx A; Hinzmann J; Diallo H; Ayouba A; Le Marcis F; Soropogui B; Ifono K; Diagne MM; Sow MS; Bore JA; Calvignac-Spencer S; Vidal N; Camara J; Keita MB; Renevey A; Diallo A; Soumah AK; Millimono SL; Mari-Saez A; Diop M; Doré A; Soumah FY; Kourouma K; Vielle NJ; Loucoubar C; Camara I; Kourouma K; Annibaldis G; Bah A; Thielebein A; Pahlmann M; Pullan ST; Carroll MW; Quick J; Formenty P; Legand A; Pietro K; Wiley MR; Tordo N; Peyrefitte C; McCrone JT; Rambaut A; Sidibé Y; Barry MD; Kourouma M; Saouromou CD; Condé M; Baldé M; Povogui M; Keita S; Diakite M; Bah MS; Sidibe A; Diakite D; Sako FB; Traore FA; Ki-Zerbo GA; Lemey P; Günther S; Kafetzopoulou LE; Sall AA; Delaporte E; Duraffour S; Faye O; Leendertz FH; Peeters M; Toure A; Magassouba NF
    Nature; 2021 Sep; 597(7877):539-543. PubMed ID: 34526718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility and safety of rVSV-ZEBOV vaccination of humanitarian health workers against Ebola virus disease: an observational study.
    Carnino L; Vetter P; Peyraud N; Aebischer-Perone S; Chappuis F; Huttner A; Kaiser L; Eperon G
    J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34128975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines.
    Montalvo Zurbia-Flores G; Rollier CS; Reyes-Sandoval A
    Hum Vaccin Immunother; 2022 Dec; 18(1):1895644. PubMed ID: 33974507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MEGA11: Molecular Evolutionary Genetics Analysis Version 11.
    Tamura K; Stecher G; Kumar S
    Mol Biol Evol; 2021 Jun; 38(7):3022-3027. PubMed ID: 33892491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The need for a new strategy for Ebola vaccination.
    Bausch DG
    Nat Med; 2021 Apr; 27(4):580-581. PubMed ID: 33820993
    [No Abstract]   [Full Text] [Related]  

  • 30. Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate.
    Roozendaal R; Hendriks J; van Effelterre T; Spiessens B; Dekking L; Solforosi L; Czapska-Casey D; Bockstal V; Stoop J; Splinter D; Janssen S; Baelen BV; Verbruggen N; Serroyen J; Dekeyster E; Volkmann A; Wollmann Y; Carrion R; Giavedoni LD; Robinson C; Leyssen M; Douoguih M; Luhn K; Pau MG; Sadoff J; Vandebosch A; Schuitemaker H; Zahn R; Callendret B
    NPJ Vaccines; 2020 Dec; 5(1):112. PubMed ID: 33335092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate.
    Sanchez-Felipe L; Vercruysse T; Sharma S; Ma J; Lemmens V; Van Looveren D; Arkalagud Javarappa MP; Boudewijns R; Malengier-Devlies B; Liesenborghs L; Kaptein SJF; De Keyzer C; Bervoets L; Debaveye S; Rasulova M; Seldeslachts L; Li LH; Jansen S; Yakass MB; Verstrepen BE; Böszörményi KP; Kiemenyi-Kayere G; van Driel N; Quaye O; Zhang X; Ter Horst S; Mishra N; Deboutte W; Matthijnssens J; Coelmont L; Vandermeulen C; Heylen E; Vergote V; Schols D; Wang Z; Bogers W; Kuiken T; Verschoor E; Cawthorne C; Van Laere K; Opdenakker G; Vande Velde G; Weynand B; Teuwen DE; Matthys P; Neyts J; Jan Thibaut H; Dallmeier K
    Nature; 2021 Feb; 590(7845):320-325. PubMed ID: 33260195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A clinician's perspective on yellow fever vaccine-associated neurotropic disease.
    Lecomte E; Laureys G; Verbeke F; Domingo Carrasco C; Van Esbroeck M; Huits R
    J Travel Med; 2020 Nov; 27(7):. PubMed ID: 32965473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small-molecule inhibitors of TBK1 serve as an adjuvant for a plasmid-launched live-attenuated yellow fever vaccine.
    Sharma S; Schmid MA; Sanchez Felipe L; Grenelle J; Kaptein SJF; Coelmont L; Neyts J; Dallmeier K
    Hum Vaccin Immunother; 2020 Sep; 16(9):2196-2203. PubMed ID: 32574095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 40-Month Follow-Up of Ebola Virus Disease Survivors in Guinea (PostEbogui) Reveals Long-Term Detection of Ebola Viral Ribonucleic Acid in Semen and Breast Milk.
    Keita AK; Vidal N; Toure A; Diallo MSK; Magassouba N; Baize S; Mateo M; Raoul H; Mely S; Subtil F; Kpamou C; Koivogui L; Traore F; Sow MS; Ayouba A; Etard JF; Delaporte E; Peeters M;
    Open Forum Infect Dis; 2019 Dec; 6(12):ofz482. PubMed ID: 32128327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limited evolution of the yellow fever virus 17d in a mouse infection model.
    Kum DB; Mishra N; Vrancken B; Thibaut HJ; Wilder-Smith A; Lemey P; Neyts J; Dallmeier K
    Emerg Microbes Infect; 2019; 8(1):1734-1746. PubMed ID: 31797751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge.
    Marzi A; Reynolds P; Mercado-Hernandez R; Callison J; Feldmann F; Rosenke R; Thomas T; Scott DP; Hanley PW; Haddock E; Feldmann H
    EBioMedicine; 2019 Nov; 49():223-231. PubMed ID: 31631035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis.
    Ferrara F; Temperton N
    Methods Protoc; 2018 Jan; 1(1):. PubMed ID: 31164554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ebola virus disease.
    Malvy D; McElroy AK; de Clerck H; Günther S; van Griensven J
    Lancet; 2019 Mar; 393(10174):936-948. PubMed ID: 30777297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pseudovirus rVSVΔG-ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice.
    McWilliams IL; Kielczewski JL; Ireland DDC; Sykes JS; Lewkowicz AP; Konduru K; Xu BC; Chan CC; Caspi RR; Manangeeswaran M; Verthelyi D
    Cell Rep; 2019 Feb; 26(7):1718-1726.e4. PubMed ID: 30759384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A yellow fever-Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice.
    Kum DB; Mishra N; Boudewijns R; Gladwyn-Ng I; Alfano C; Ma J; Schmid MA; Marques RE; Schols D; Kaptein S; Nguyen L; Neyts J; Dallmeier K
    NPJ Vaccines; 2018; 3():56. PubMed ID: 30564463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.